Every 8-K that Covista Inc (CVSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CVSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVSA filings page.
Covista Inc. reported higher fourth-quarter and fiscal 2026 results for the year ended June 30, 2026, and stated it exceeded its fiscal 2026 and long-term financial targets while completing its three-year Growth with Purpose strategy. Full-year revenue from continuing operations was $1,954,085 (in thousands), up 9.3% year over year, with Q4 revenue of $501,382 (in thousands), up 9.7%, and total Q4 enrollment up 8.4%.
Net income was $251,566 (in thousands) and diluted EPS was $7.04. Adjusted EPS was $8.25, a 23.7% increase from $6.67. Adjusted EBITDA rose to $521,736 (in thousands), a 13.5% increase. Net cash provided by operating activities from continuing operations reached $470,796 (in thousands). Net leverage was 0.5x, based on net debt of $266,684 (in thousands).
By segment, Chamberlain grew revenue 3.4% for the year, Walden 16.1%, and Medical and Veterinary 8.1%. Walden’s total students increased 14.0%, and Medical and Veterinary students grew 7.3%. Chamberlain’s full-year operating income declined 6.5%. Covista launched its next strategy phase, Purpose at Scale, and initiated fiscal 2027 guidance.
Covista Inc. has appointed Ms. Emily Chiu and Ms. Leslie Storms as independent members of its Board of Directors, effective August 17, 2026. Both will stand for re-election at Covista’s 2026 annual meeting of stockholders, and future committee assignments will be determined by the Board.
Each new director will receive a prorated grant of restricted stock units with a grant date fair value of approximately $32,986.00 on August 17, 2026, an additional equity retainer restricted stock unit grant valued at $150,000.00 immediately following the annual meeting, and annual cash compensation of $85,000.00 paid quarterly. Covista states there are no appointment arrangements or related-party transactions requiring disclosure, and the Board size will increase from ten to twelve members effective August 17, 2026.
Covista Inc. reported third quarter fiscal 2026 results showing steady growth and stronger guidance. Revenue for the quarter was $487.0 million, up 4.5% year over year, with operating income edging up to $91.3 million. Net income from continuing operations was $58.0 million, while a loss from discontinued operations reduced total net income to $41.6 million.
Total students surpassed 100,000, with enrollment up 6.8% year over year and growth in every segment. Chamberlain revenue rose 2.3% with slightly higher operating income, Walden revenue grew 4.6% but with lower operating income, and Medical and Veterinary revenue increased 8.9% with operating income up 18.7%.
For the full fiscal year 2026, Covista raised its revenue outlook to $1,930–$1,945 million, or about 8–9% growth, and lifted adjusted earnings per share guidance to $7.95–$8.15, or roughly 19–22% growth year over year. Adjusted EBITDA for the quarter was $127.9 million, and net leverage stood at 0.7x, supported by strong cash generation and reduced long-term debt.
Covista Inc. furnished an investor newsletter dated April 9, 2026, providing updates on key milestones, strategic developments, and operational progress. The newsletter is attached as Exhibit 99.1 and is incorporated by reference for informational purposes.
The company emphasizes that the newsletter and related information under Regulation FD are furnished, not filed, so they are not subject to certain Exchange Act liabilities and are not automatically incorporated into other securities law filings. Covista also includes standard cautionary language that the newsletter contains forward-looking statements subject to risks described in its most recent Form 10-K and other SEC filings.